Virtu Financial LLC Purchases 13,632 Shares of Neurocrine Biosciences, Inc. $NBIX

Virtu Financial LLC raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 775.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 15,389 shares of the company’s stock after purchasing an additional 13,632 shares during the quarter. Virtu Financial LLC’s holdings in Neurocrine Biosciences were worth $2,183,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock valued at $388,435,000 after buying an additional 1,263,633 shares during the last quarter. Norges Bank bought a new position in Neurocrine Biosciences in the 4th quarter worth $162,664,000. UBS Group AG lifted its holdings in Neurocrine Biosciences by 169.8% during the fourth quarter. UBS Group AG now owns 983,528 shares of the company’s stock valued at $139,494,000 after purchasing an additional 618,956 shares in the last quarter. Zurich Insurance Group Ltd FI purchased a new stake in shares of Neurocrine Biosciences in the fourth quarter worth $65,162,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Neurocrine Biosciences in the third quarter worth $48,791,000. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on NBIX. Leerink Partners raised their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Piper Sandler increased their price target on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. HC Wainwright raised their price target on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Finally, Canaccord Genuity Group upped their price objective on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $187.52.

Neurocrine Biosciences Price Performance

NBIX stock opened at $158.29 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $169.57. The firm has a market capitalization of $15.92 billion, a P/E ratio of 24.39, a price-to-earnings-growth ratio of 1.19 and a beta of 0.40. The company has a fifty day simple moving average of $148.53 and a two-hundred day simple moving average of $140.84.

Insider Activity

In related news, insider Julie Cooke sold 36,937 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $156.22, for a total value of $5,770,298.14. Following the completion of the transaction, the insider owned 22,374 shares in the company, valued at approximately $3,495,266.28. This trade represents a 62.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 2,261 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $156.71, for a total value of $354,321.31. Following the sale, the insider directly owned 16,225 shares in the company, valued at $2,542,619.75. The trade was a 12.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 355,234 shares of company stock worth $55,330,060. 4.60% of the stock is owned by insiders.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.